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Abstract
Background: Cisplatin-based chemoradiation is the standard of care for locally advanced cervical cancer patients; however,
neoadjuvant modalities are currently being tested. Neoadjuvant studies in several tumor types have underscored the prognostic
significance of pathological response for survival; however there is a paucity of studies in cervical cancer investigating this issue.
Methods: Four cohorts of patients with locally advanced cervical carcinoma (stages IB2-IIIB); included prospectively in phase II
protocols of either neoadjuvant chemotherapy with 1) cisplatin-gemcitabine, 2) oxaliplatin-gemcitabine, 3) carboplatin-paclitaxel
or 4) chemoradiation with cisplatin or cisplatin-gemcitabine followed by radical hysterectomy were analyzed for pathological
response and survival.
Results: One-hundred and fifty three (86%) of the 178 patients treated within these trials, underwent radical hysterectomy and
were analyzed. Overall, the mean age was 44.7 and almost two-thirds were FIGO stage IIB. Pathological response rates were as
follows: Complete (pCR) in 60 cases (39.2%), Near-complete (p-Near-CR) in 24 (15.6 %) and partial (pPR) in 69 cases (45.1%).
A higher proportion rate of pCR was observed in patients treated with chemoradiotherapy (with cisplatin [19/40, 47.5%]; or
with cisplatin-gemcitabine [24/41, 58.5%] compared with patients receiving only chemotherapy, 6/23 (26%), 3/8 (37.5%) and 8/
41 (19.5%) for cisplatin-gemcitabine, oxaliplatin-gemcitabine and carboplatin-paclitaxel respectively [p = 0.0001]). A total of 29
relapses (18.9%) were documented. The pathological response was the only factor influencing on relapse, since only 4/60 (6.6%)
patients with pCR relapsed, compared with 25/93 (26.8%) patients with viable tumor, either pNear-CR or pPR (p = 0.001).
Overall survival was 98.3% in patients with pCR versus 83% for patients with either pNear-CR or pPR (p = 0.009).
Conclusion: Complete pathological response but no Near-complete and partial responses is associated with longer survival in
cervical cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.
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Background
Cervical cancer remains as one of the biggest killers in
women around the world. The epidemiology of cervical
cancer is strongly related to the standard of living of pop-
ulations, thus, underdeveloped countries present the
higher mortality rates which can be as high as >70 per 100
000 inhabitants and most cases are diagnosed in locally
advanced disease -stages IB2-IVA- according to the FIGO
classification [1].
Five randomized studies have demonstrated that survival
with radiation therapy alone is lower than with radiation
therapy with concomitant chemotherapy based on cispla-
tin [2-6]. Afterwards, a meta-analysis corroborated these
findings confirming that chemoradiation offers an abso-
lute survival benefit at 5 years of 12% [7]. Thus, cisplatin-
based chemoradiation was largely accepted as the stand-
ard of care for cervical cancer patients whose treatment
requires radiation. However, not only concomitant chem-
oradiotherapy has shown benefit in locally advanced cer-
vical cancer; a meta-analysis of neoadjuvant
chemotherapy followed by radical hysterectomy has also
shown an absolute benefit of 15% at 5-year survival [8];
currently, the EORTC is conducting a randomized phase
III trial comparing these two treatment modalities. On the
other hand, multimodal treatments incorporating radia-
tion, chemotherapy and surgery must be investigated in
the aim to further improve the prognosis [9].
Studies in breast carcinoma, one of the tumors most fre-
quently treated with neoadjuvant chemotherapy have
underscored the importance of achieving a major or com-
plete pathological response to prolong survival. In gen-
eral, higher pathological complete response rate correlates
with better survival [10,11]. On these bases it can be
hypothesized that more effective neoadjuvant modalities
would produce longer survival by increasing the patho-
logical complete response rates.
There exists limited information on the value of patholog-
ical response for predicting survival in cervical cancer
patients treated with neoadjuvant modalities. In particu-
lar, the meaning of pathological complete, near-complete
(microscopic residual) or partial response remains unset-
tled. To investigate this issue, we have reviewed the out-
come of the patients that underwent surgery in our series
of phase II studies of neoadjuvant chemotherapy or chem-
oradiation followed by radical hysterectomy.
Methods
Four phase II studies were performed on FIGO staged IB2-
IIIB patients diagnosed with cervical squamous cell carci-
noma, adenocarcinoma or adenosquamous carcinoma at
the National Institute of Cancerology. Patients had to
meet the following criteria in order to be included: 1) No
previous oncological treatment; 2) older than 18 years old
and younger than 70 years old; 3) functional status of 0-2
according to the WHO classification; 4) normal hemato-
logical, hepatic, renal and respiratory function according
to the following parameters: hemoglobin >9 gr/L, leuko-
cyte count >4000/mm3, and platelets > 100 000/mm3;
total bilirubin and transaminases <1.5 times the high nor-
mal value; normal serum creatinine; 5) normal poster-
oanterior radiograph of the thorax; and 6) informed
consent. The Institutional Regulatory Boards of the
National Institute of Cancerology approved the protocols.
Patients with history of cancer, severe systemic or uncon-
trolled metabolic diseases, neuropathy or psychiatric dis-
orders were excluded.
Clinical staging was performed without anesthesia at least
by two physicians of the Gynecology and Radiotherapy
Departments. In the case of disagreement, the evaluation
of an additional examiner was asked.
Treatment protocols
Neoadjuvant cisplatin gemcitabine followed by radical hysterectomy
Treatment, toxicity and response evaluation details have
been previously published [12]. Patients received 3
courses every 21 days of cisplatin at 100 mg/m2 on day 1,
and 1000 mg/m2 of gemcitabine on days 1 and 8.
Neoadjuvant oxaliplatin gemcitabine followed by radical 
hysterectomy
Treatment, toxicity and response evaluation details have
been previously published [13]. Patients received 3
courses every 21 days of oxaliplatin at 130 mg/m2 on day
1, and 1250 mg/m2 gemcitabine on days 1 and 8.
Neoadjuvant carboplatin paclitaxel followed by radical hysterectomy
Treatment, toxicity and response evaluation details have
been previously published [14]. Patients received 3
courses every 21 days with carboplatin at a dose calculated
according with an area under the curve (AUC) of 6, and
paclitaxel at 175 mg/m2 both on day 1.
Neoadjuvant chemoradiation with cisplatin or cisplatin gemcitabine 
followed by radical hysterectomy
Treatment, toxicity and response evaluation details have
been previously published [15]. This was a randomized
phase II study where we compared cisplatin (weekly at 40
mg/m2 for six) versus cisplatin gemcitabine (weekly at 40
mg/m2 and 125 mg/m2 respectively, both for six) concur-
rent to external beam radiation (50–56 Gy in 5 weeks with
2 Gy fractions) followed by radical hysterectomy.
In all these four trials, radical hysterectomy was per-
formed within 5 weeks after the neoadjuvant treatment, if
it was clinically considered that resection would be possi-
ble obtaining free surgical margins. In case of unresectableInternational Seminars in Surgical Oncology 2006, 3:3 http://www.issoonline.com/content/3/1/3
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tumors, patients in trials of neoadjuvant chemotherapy
received definitive treatment with radiation therapy (tele-
therapy and brachytherapy) plus 40 mg/m2 weekly cispla-
tin for 6 applications during teletherapy. In the
neoadjuvant chemoradiation trial, patients with any path-
ological response less than complete or near-complete
received brachytherapy. In addition, in the neoadjuvant
cisplatin gemcitabine no postoperative radiation was used
regardless of the pathological response, whereas in the
oxaliplatin gemcitabine adjuvant chemoradiation was
used in all cases with a pathological response less than
complete; and in the carboplatin paclitaxel, only in those
cases with partial response (no chemoradiation in com-
plete or near-complete response).
Follow-up
Follow-up included pelvic examination every 3 months
starting at treatment completion. Imaging studies, such as
CT scan, were performed when considered clinically indi-
cated.
Evaluation of pathological response
Pathological evaluation of tumor was done by a patholo-
gist who was blinded to the treatment received by the
patient. Complete cervix was included for analysis and the
response was registered as follows: Patients with no resid-
ual viable tumor cells in the surgical specimen (primary
tumor and lymph nodes T0N0M0) were classified as hav-
ing a pathological complete response (pCR); near-complete
or microscopic response was defined with the presence of
one or more foci of malignant viable cells measuring less
than 1 millimeter and partial response when the residual
tumor was larger than 1 millimeter.
Statistical analysis
Overall survival was estimated using the Kaplan-Meier
method [16] from the date of diagnosis to date of death or
last follow-up. The influence of variables on survival was
analyzed using the Cox regression analysis [17]. All statis-
tical tests were two-sided, with significance defined as p <
0.05. All analysis was performed using SPSS-10 software.
Results
Characteristics of patients
Out of 178 patients treated within these trials, 86% (153
patients) were submitted to radical hysterectomy and are
subjected to this analysis. Overall, the mean age was 44.78
(range 24–67) and almost two-thirds (91, 59.4 %) were
IIB. Stage distribution according to protocol treatment is
shown in table 1.
Treatment and pathological response by group of 
treatment
Neoadjuvant cisplatin gemcitabine followed by radical
hysterectomy. This study included 41 patients or which 23
underwent surgery. Six 6 (26%) patients had pCR and 17
pPR.
Neoadjuvant gemcitabine oxaliplatin followed by radical
hysterectomy. This study included 10 patients. Only 8 of
Table 2: Distribution of pathological response in treatment groups
Neoadjuvant protocol Complete response Near-complete Partial response Total
cisplatin + gemcitabine 6 - 17 23
carboplatin + paclitaxel 8 4 29 41
oxaliplatin + gemcitabine 3 3 2 8
CT/RT with cisplatin 19 8 13 40
CT/RT with cisplatin + gemcitabine. 24 9 8 41
Total 60 24 69 153
Table 1: Clinical stage according to neoadjuvant protocol for operated patients
Neoadjuvant protocol Clinical stage Total
1B2 IIA IIB IIIA IIIB
cisplatin + gemcitabine 2 3 14 0 4 23
carboplatin + paclitaxel 7 7 22 1 4 41
oxaliplatin + gemcitabine 2 1 4 0 1 8
CT/RT with cisplatin 9 4 27 0 0 40
CT/RT with cisplatin + gemcitabine 8 9 24 0 0 41
Total 28 24 91 1 9 153International Seminars in Surgical Oncology 2006, 3:3 http://www.issoonline.com/content/3/1/3
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them underwent radical hysterectomy, of which three
(37.5%) patient attained pCR, three (37.5%) had pNear-
CR and two pPR (25%).
Neoadjuvant carboplatin paclitaxel followed by radical
hysterectomy. This study included 43 patients. Of these
patients, 41 (95%) underwent radical hysterectomy
obtaining pCR and pNear-CR in 8 (19.5%) and 4 (9.7%)
patients, respectively. The remaining 29 (70.7%) patients
had pPR.
Preoperative chemoradiation with cisplatin or cisplatin
gemcitabine. Eighty-three patients were included in this
randomized trial. Of these 40 were in the cisplatin arm
and all were operated; 43 received cisplatin and gemcitab-
ine and 41 underwent surgery. Pathological complete,
near-complete and partial responses were as follows: cis-
platin arm: 19 (47.5%), 8 (20 %) and 13 (32.5%) whereas
in the cisplatin gemcitabine arm rates were: 24 (58.5%), 9
(22.5%) and 8 (19.5 %) respectively.
Summarizing, pathological response rates were as fol-
lows: pCR in 60 cases (39.2 %), pNear-CR in 24 (15.6 %)
and pPR in 69 cases (49.2%). A higher proportion rate of
pCR was observed in patients treated with chemoradio-
therapy (with cisplatin [19/40, 47.5%]; or with cisplatin-
gemcitabine [24/41, 58.5%]) compared with patients
receiving only chemotherapy, 6/23 (26%), 3/8 (37.5%)
and 8/41 (19.5 %) for cisplatin-gemcitabine, oxaliplatin-
gemcitabine and carboplatin-paclitaxel respectively (p =
0.0001), table 2.
Relapse rate
A total of 29 relapses (18.9%) were documented. The
analysis of relapse rate, according with the neoadjuvant
treatment, and clinical stage showed no statistical signifi-
cant difference among all modalities administered (p =
0.06), as well as initial clinical stage (p = 0.53). The path-
ological response was the only factor influencing on
relapse, since only 4/60 (6.6%) patients with pCR
relapsed, compared with 5/24 (20.8 %) or 20/69 (28.9 %)
in patients with pNear-CR, or pPR, respectively (p =
0.001).
Overall survival
Survival analysis was restricted to the 153 patients that
underwent radical hysterectomy. At a median follow-up
time of 29.6 months (2.9–66.4) for all patients, 5-year-
overall survival was 98.3% in patients with pCR versus
83% for patients with either pNear-CR or pPR (p = 0.009)
(Figure 1a). Among the ones with no pCR no difference in
5-year overall survival was found between patients with
pNear-CR compared with those with pPR (Figure 1b). Cox
multivariate analysis was done to underscore factors influ-
encing on survival. The only prognostic factor influencing
on overall survival was pathological response (p = 0.008,
95 % CI: 1.103 -1.953). Neither the type of neoadjuvant
treatment (p = 0.639, 95%CI: 0.710 -1.748), nor the ini-
tial clinical stage (p = 0.531, 95 % CI: 0.707–1.959): were
factors determining the overall survival.
Discussion
Currently, cisplatin-based chemoradiation is the standard
of care for locally advanced cervical carcinoma [9]. This
combined treatment has of proven efficacy even in
patients treated outside of clinical trials which is certainly
important as this neoplasm mainly affects socially disad-
vantaged women who may not comply with the treatment
[18]. Nevertheless, the 5-year survival of locally advanced
cervical cancer patients is around 70% hence other thera-
peutic approaches must be tested in order to further
improve prognosis. Among these, neoadjuvant chemo-
therapy and neoadjuvant chemoradiation are being tested
in phase III randomized trials.
A number of studies of neoadjuvant chemotherapy or
concurrent chemoradiation in several tumor types under-
score the importance of achieving a major or complete
pathological response to prolong survival. Although it has
been argued that patients with no residual carcinoma
have a better outcome because of selection bias rather
than the effects of preoperative therapy, if a high patho-
logical complete response rate correlates with better sur-
vival then it can be hypothesized that more effective
neoadjuvant modalities would produce longer survival by
increasing the pathological complete response rates.
There are some indications that at least for cervical cancer
this may hold true. Chang et al., [19] performed a rand-
omized trial in IB bulky patients of neoadjuvant chemo-
therapy using the "quick scheme" of cisplatin 50 mg/m2
day 1, bleomycin 25 mg/m2 days 1–3, and vincristine 1
mg/m2 day 1, repeated every 10 days for three courses
against pelvic radiotherapy alone. They found no differ-
ences in survival which can be the result of the low rate
(4.6%) of pathological complete response rate. Other
phase II trials using these "old regimens" report similar
low rates of pathological responses; such as 6.6% by Singh
et al., [20], 9.5% by Porzio [21], 7% by Kim [22], and 12%
by Benedetti-Panici et al., [23]. On the contrary, with
newer regimens of chemotherapy incorporating drugs
such as gemcitabine [12,13], vinorelbine [24], paclitaxel
[14,25] or irinotecan [26], complete pathological
response rates are higher which may lead potentially to
better survival rates. In this sense, we have reported in a
comparison of two consecutive phase II trials similar sur-
vival of neoadjuvant chemotherapy with cisplatin gemcit-
abine followed by surgery in which complete pathological
response was 26% versus chemoradiation with cisplatin
in locally advanced cervical carcinomas [27], but betterInternational Seminars in Surgical Oncology 2006, 3:3 http://www.issoonline.com/content/3/1/3
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survival with that neoadjuvant treatment than radiation
alone [28]. Pending confirmation from the randomized
phase III trial that is ongoing in the EORTC it is very likely
that neoadjuvant chemotherapy followed by surgery at
best would be equivalent that the current standard of
chemoradiation. These data strongly suggest that neoad-
juvant chemotherapy trials need to be even more effective
to show superiority over standard chemoradiation. How-
ever, so far there are no indications of such superiority
with current drugs or combinations. For instance, a phase
III trial of neoadjuvant chemotherapy in cervical cancer
comparing a doublet -ifosfamide and cisplatin versus a tri-
plet -ifosfamide, cisplatin and paclitaxel found no better
results on survival by the incorporation of a third drug
[29]. These results have led investigators to assay neoadju-
vant chemoradiation instead of only chemotherapy to
improve pathological responses and survival.
Several prospective phase II trials of preoperative chemo-
radiation with cisplatin and 5-fluorouracil have been per-
formed. Resbeut et al., reported a complete pathological
response rate of 40% in 40 patients staged from IB to IVA
[30]; Jurado et al., reported a complete pathological
response rate of 67.5% in 40 patients [31] while the com-
plete pathological response rate was 54.2% in 25 patients
staged as IIB-IIIA in a third study [32]. Interestingly, the
disease-free and overall survival these trials reported is
very encouraging further supporting the hypothesis than
prognosis can be improved by highly effective neoadju-
vant therapies. In line with that, we performed a rand-
omized phase II trial comparing cisplatin versus cisplatin
Overall survival according to type of response Figure 1
(A) Overall survival according to type of response. At a median follow-up time of 29.6 months (2.9–66.4), the survival for com-
plete pathological response is 98.3% whereas is 83% for those with near-complete and partial response, (p = 0.009). (B) Over-
all survival for those with a response less than complete (near-complete and partial response). The survival for near-complete 
is 83.3% whereas is 82.3% for those with partial response (p = 0.820).
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and gemcitabine as sensitizers to radiation. Our results
demonstrate that pathological complete responses can be
indeed increased from 47.5% with cisplatin to 58.5% by
adding gemcitabine, a powerful radiosensitizer to cispla-
tin [15].
There exists limited information on the value of patholog-
ical response for predicting survival in cervical cancer
patients treated with neoadjuvant modalities. In particu-
lar, the meaning of pathological complete, near-complete
(microscopic residual) or partial response remains unset-
tled. The results of this analysis shed some light on this
issue. We found that for cervical cancer a complete patho-
logical response by either neoadjuvant chemotherapy or
neoadjuvant chemoradiation is indicative of very favora-
ble survival whereas we found no different prognosis for
those with no complete response irrespective of the
"amount" of residual disease either microscopic (near-
complete response) or minor or not change in disease
(partial response). Resbeut et al., [30] made no distinction
between complete and microscopic (near-complete)
responses, instead they reported only complete or partial
pathological response, nor integrated pathological
response to their survival analysis, however; only one of
the 16 patients with complete response had local recur-
rence suggesting its association with good prognosis.
Jurado et al., defined complete pathological response as
tumor eradication higher than 95% and found a 9-year
local control rate of 100% versus 78% (p = 0.004) and
overall survival of 93% versus 70% (p = 0.038) for com-
plete and partial responders respectively [31]. Finally,
Mancuso's study registered complete, near-complete (as
microscopic residual) and partial (as macroscopic resid-
ual) and reported no local failures among the 13 patients
with complete response suggesting that complete
responders have the most favorable prognosis [31,32].
The prognostic significance of pathological complete
response is also suggested in the setting of pre-exentera-
tive chemotherapy for recurrent cervical cancer patients.
In such modality, only one of four patients with patholog-
ical complete response and two out of four with residual
disease relapsed [33].
The discrepancy in the prognostic significance of com-
plete versus near-complete also called as major response
or microscopic residual is also observed in other tumors.
In rectal and non-small cell lung treated with chemoradi-
ation [34,35] and bladder cancer treated with chemother-
apy [36], complete and near-complete were predictive of
better survival whereas in breast cancer the better progno-
sis is not observed for any response less than complete
[37-39]. Whether the different prognostic meaning of
pathological responses result from technical issues such as
the number of patients and follow-up in studies, methods
for analyzing and reporting the surgical specimens or
result from the type of neoadjuvant treatment or even the
type of tumor needs to be further studied. It is important
however, to emphasize that among the studies on cervical
cancer, the present report is the one reporting the higher
number of patients and under two different neoadjuvant
treatments which strengths our results on the prognostic
significance of complete but no near-complete or partial
pathological response.
Conclusion
Complete pathological response but no near-complete
and partial responses are associated with very favorable
survival in cervical cancer patients treated with neoadju-
vant chemotherapy or chemoradiotherapy. These data
strongly suggest that every effort must be made to obtain
a high pathological complete response rate in order to
improve survival. The value of adjuvant therapies for
patients with a pathological response less than complete
must be investigated in this subset of locally advanced cer-
vical cancer patients treated under neoadjuvant protocols.
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